Floatz logo

Treg Cells

Hematologic Malignancies

Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

51 Active assets in the Hematologic Malignancies cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 2BB
Evomela
Thomas Jefferson University
Phase 2BB
cc-5013
CellCentric Ltd.
Phase 4BB
Monomethyl Fumarate
National Cancer Institute (NCI)
Phase 2BB
TACROLIMUS
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Treg Cells is also rated in:

myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →